• Publications
  • Influence
Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors
Background Patients with advanced midgut neuroendocrine tumors who have had disease progression during first‐line somatostatin analogue therapy have limited therapeutic options. This randomized,Expand
  • 886
  • 65
  • PDF
Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well‐Differentiated Disease
&NA; Neuroendocrine tumors (NETs) comprise a heterogeneous group of malignancies that arise from neuroendocrine cells throughout the body, most commonly originating from the lungs andExpand
  • 93
  • 10
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.
Purpose Metastatic pancreatic ductal adenocarcinoma is characterized by excessive hyaluronan (HA) accumulation in the tumor microenvironment, elevating interstitial pressure and impairing perfusion.Expand
  • 153
  • 9
Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas.
UNLABELLED Patients with pancreatic and biliary carcinomas lack personalized treatment options, in part because biopsies are often inadequate for molecular characterization. Cell-free DNA (cfDNA)Expand
  • 144
  • 9
  • PDF
A Meta-Analysis of Osteosarcoma Outcomes in the Modern Medical Era
Four decades ago, specialized chemotherapy regimens turned osteosarcoma, once considered a uniformly fatal disease, into a disease in which a majority of patients survive. Though significant survivalExpand
  • 274
  • 8
  • PDF
Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer.
BACKGROUND Identifying molecular markers for tumor recurrence is critical in successfully selecting patients with stage III colon cancer who are more likely to benefit from adjuvant chemotherapy. TheExpand
  • 111
  • 5
Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial
Importance KRAS mutations are common in pancreatic cancer, but directly targeting the KRAS protein has thus far been unsuccessful. The aim of this trial was to block the MEK and PI3K/AKT pathwaysExpand
  • 65
  • 5
Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity.
BACKGROUND Despite the success of modern chemotherapy in the treatment of large bowel cancers, patients with metastatic gastric cancer continue to have a dismal outcome. Identifying predictive andExpand
  • 118
  • 4
Pancreatic cancer cachexia: a review of mechanisms and therapeutics
Over the last decade, we have gained new insight into the pathophysiology of cachexia associated with pancreatic cancer. Unfortunately, its treatment is complex and remains a challenge. PancreaticExpand
  • 70
  • 4
  • PDF
Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas.
AIM This randomised phase III trial evaluated first-line trabectedin versus doxorubicin-based chemotherapy (DXCT) in patients with advanced/metastatic translocation-related sarcomas (TRS). METHODSExpand
  • 94
  • 3